Barry J.  Simon net worth and biography

Barry Simon Biography and Net Worth

Director of ImmunityBio

Barry J. Simon, M.D., is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He previously served on Viracta’s board from July 2017 to November 2020 and has been serving as Director and CCAO of Immunity Bio, Inc. since March 2021.  Prior to this, he served as President and Chief Administrative Officer of Nantkwest, Inc. since 2015 and as its President and CEO since 2007. Dr. Simon also serves on the boards of Cue BioPharma and Brink Biologics Inc. He has broad experience in public and private companies, having led private and public equity offerings, product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, IND and BLA regulatory filings, human-enabling programs, and manufacturing, quality control and life cycle management projects. Previously, he held Vice President, senior level and advisory positions at F. Hoffmann-La Roche, Roche Labs, Connetics Corporation, Immunomedics, Immusol, HealthPro BioVentures, LLC, and NorthSound Capital, LLC.

In his prior roles, Dr. Simon worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on product launches including Xeloda®, Pegasys®, Fortovase®, Tamiflu®, Camptobell®, Boniva®, Fuzeon®, Valcyt®, and Accutane®. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He received his M.D. from the SUNY Downstate Health Sciences Center in New York and trained clinically in infectious diseases, anesthesiology, and internal medicine at Albert Einstein College of Medicine, The Mount Sinai Medical Center and New York University, respectively.

What is Barry J. Simon's net worth?

The estimated net worth of Barry J. Simon is at least $9.09 million as of May 21st, 2021. Dr. Simon owns 3,212,517 shares of ImmunityBio stock worth more than $9,091,423 as of December 17th. This net worth evaluation does not reflect any other assets that Dr. Simon may own. Learn More about Barry J. Simon's net worth.

How old is Barry J. Simon?

Dr. Simon is currently 59 years old. There are 6 older executives and no younger executives at ImmunityBio. The oldest executive at ImmunityBio is Dr. Patrick Soon-Shiong F.A.C.S., FRCS, who is 71 years old. Learn More on Barry J. Simon's age.

How do I contact Barry J. Simon?

The corporate mailing address for Dr. Simon and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Barry J. Simon's contact information.

Has Barry J. Simon been buying or selling shares of ImmunityBio?

Barry J. Simon has not been actively trading shares of ImmunityBio in the last ninety days. Most recently, Barry J. Simon sold 21,223 shares of the business's stock in a transaction on Monday, May 24th. The shares were sold at an average price of $16.02, for a transaction totalling $339,992.46. Following the completion of the sale, the director now directly owns 3,212,517 shares of the company's stock, valued at $51,464,522.34. Learn More on Barry J. Simon's trading history.

Who are ImmunityBio's active insiders?

ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.

Barry J. Simon Insider Trading History at ImmunityBio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/24/2021Sell21,223$16.02$339,992.463,212,517View SEC Filing Icon  
5/21/2021Sell14,990$16.09$241,189.103,212,517View SEC Filing Icon  
See Full Table

Barry J. Simon Buying and Selling Activity at ImmunityBio

This chart shows Barry J Simon's buying and selling at ImmunityBio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ImmunityBio Company Overview

ImmunityBio logo
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Read More

Today's Range

Now: $2.84
Low: $2.76
High: $2.85

50 Day Range

MA: $4.54
Low: $2.83
High: $6.17

2 Week Range

Now: $2.84
Low: $2.76
High: $10.53

Volume

1,594,820 shs

Average Volume

5,041,289 shs

Market Capitalization

$1.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86